CereMark touts new patents for PET Alzheimer's agent

AuntMinnie.com staff writers
Aug 3, 2022
2019 10 23 18 31 0645 Patent Stamp 20191023184409

Radiopharmaceutical developer CereMark announced that additional patents have been awarded to the University of California, Los Angeles (UCLA) for a PET agent that the company licensed from the university for the imaging of Alzheimer's disease.

The patents are associated with F-18 flornaptitril (also known as F-18 FDDNP), a biomarker for the detection, development, and progression of Alzheimer's disease, as well as chronic traumatic encephalopathy and other neurodegenerative diseases.

The patents cover a synthesizing method that allows for high radiochemical yields and short manufacturing times for administration.

CereMark is UCLA's only licensee for the development and commercialization of F-18 flornaptitril, and the company is preparing for a phase 3 clinical multisite study required for U.S. Food and Drug Administration approval.

Latest in Molecular Imaging
Examples in two patients. (Top) Abnormal leukocyte accumulation was observed in the right 1st to 5th toes, with the radioactive lesions extending to the bone, indicating osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). Two spherical VOIs were drawn on diabetic foot infections (DFIs) and the highest SUVmax was 4.2 (higher than the cutoff of 1.1) Despite intensive treatment, the infection progressed, leading to the patient undergoing right below knee amputation 43 days after SPECT/CT. (Bottom) Mild focal abnormal leukocyte accumulation was detected in the right 3rd and 4th toes. The lesions were in contact with the bone, which raised a suspicion of osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). A circular VOI was drawn on DFIs and the SUVmax was 1.0 (lower than the cutoff of 1.1). After 10 weeks of antibiotic treatment, the infection was successfully resolved, and the foot was preserved. Image and caption courtesy of Scientific Reports.
SPECT/CT predicts foot amputations in diabetics
April 24, 2024
Ppgl 167 250
PET/CT superior to MRI for detecting spinal bone metastases
April 23, 2024
Driving the future of PET/CT.
Sponsored
Driving the future of PET/CT.
April 17, 2024
Tspo Thumbnail
PET/MRI reveals sex differences in patients with autism
April 18, 2024
Related Stories
2018 12 11 00 02 7009 Atom Nuclear Lab 400
Nuclear Medicine
SpectronRx to supply PET radiotracer for CereMark's clinical trials
2021 04 30 22 31 6660 2021 04 30 Ceremark Patent 20210430221952
Molecular Imaging
CereMark touts patent for PET radiotracer
2021 07 12 17 41 2151 Business Men Handshake 400
Molecular Imaging
Radiopharm collaborates with Lantheus on theranostic agent
Driving the future of PET/CT.
Sponsor Content
Driving the future of PET/CT.
More in Molecular Imaging
SPECT/CT predicts foot amputations in diabetics
By Will Morton
Technetium-99m white blood cell SPECT/CT imaging may be useful for identifying diabetic patients at risk of amputations due to foot infections.
April 24, 2024
Examples in two patients. (Top) Abnormal leukocyte accumulation was observed in the right 1st to 5th toes, with the radioactive lesions extending to the bone, indicating osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). Two spherical VOIs were drawn on diabetic foot infections (DFIs) and the highest SUVmax was 4.2 (higher than the cutoff of 1.1) Despite intensive treatment, the infection progressed, leading to the patient undergoing right below knee amputation 43 days after SPECT/CT. (Bottom) Mild focal abnormal leukocyte accumulation was detected in the right 3rd and 4th toes. The lesions were in contact with the bone, which raised a suspicion of osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). A circular VOI was drawn on DFIs and the SUVmax was 1.0 (lower than the cutoff of 1.1). After 10 weeks of antibiotic treatment, the infection was successfully resolved, and the foot was preserved. Image and caption courtesy of Scientific Reports.
PET/CT superior to MRI for detecting spinal bone metastases
By Will Morton
Gallium-68 (Ga-68) DOTATATE PET/CT appears to be the best approach for detecting spinal bone metastases in patients with certain neuroendocrine tumors.
April 23, 2024
Ppgl 167 250
Neuroimaging detects blast exposure brain injuries in U.S. soldiers
By Will Morton
A battery of MRI and PET neuroimaging tests show patterns of brain injury in active-duty U.S. soldiers caused by repeated blast exposures.
April 22, 2024
Military
PET/MRI reveals sex differences in patients with autism
By Will Morton
PET/MRI shows that young women with autism spectrum disorder have increased brain metabolism associated with translocator protein.
April 18, 2024
Tspo Thumbnail
PET tracer for gliomas under expedited review
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Telix Pharmaceuticals’ PET radiotracer F-18 floretyrosine (Pixclara) for imaging progressive or recurring gliomas.
April 17, 2024
Gliomas
FAPI-PET shows promise in patients with lung cancer
By Will Morton
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans.
April 15, 2024
F-18 FDG and Ga-68 FAPI-46 images of a 51-year-old woman with adenocarcinoma with lepidic growth pattern in right upper lobe. (A) Maximum-intensity-projection PET images. The lesion had F-18 FDG uptake below blood pool level but was strongly Ga-68 FAPI-46-positive. CT-guided biopsy led to pathologic diagnosis of adenocarcinoma, and the patient was treated by stereotactic body radiation therapy because of functional inoperability. Image courtesy of the Journal of Nuclear Medicine.
Vision transformer AI model boosts PET/CT imaging of cancer
By Will Morton
A vision transformer AI model outperformed convolutional neural networks when classifying tumors on PET/CT images as benign or malignant.
April 12, 2024
Predictions and Grad-CAMs of ViT-based models on sample PET/CT, PET, and CT test images from the “positive” class. ViT was fine-tuned using training data for each modality. The bounding boxes depicted in the figure indicate malignant lesions. The top row of the Grad-CAMs shows important areas for “positive” predictions, and the bottom row shows areas for “negative” predictions. Image courtesy of Scientific Reports.
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
PET/MRI detects brain injury in pediatric cancer survivors
By Will Morton
PET/MRI could be a tool for diagnosing brain injury due to high-dose methotrexate treatment in young cancer survivors.
April 8, 2024
A visual abstract of the study. Image courtesy of the Journal of Nuclear Medicine.
Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
By AuntMinnie.com staff writers
Life Molecular Imaging and Sofie Biosciences have begun offering the Neuraceq PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio.
April 5, 2024
Brain Puzzle Dementia Social
CDL Nuclear Technologies launches mobile cardiac PET/CT trailer
By AuntMinnie.com staff writers
The company said the mobile trailer complements its other services, which include PET/CT buildouts and on-demand daily use rubidium-82 radioisotope services.
April 5, 2024
Pet Ct Machine
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
Page 1 of 592
Next Page